Nanostics Inc.
Nanostics Inc.

John Lewis, CEO Frank & Carla Sojonky Chair in Prostate Cancer Research Professor, Department of Oncology (University of Alberta)

Edmonton, Alberta

Nanostics Inc.

Clarity DX Prostate, a new blood test to diagnose and predict prostate cancer.

Health Innovation

ClarityDX Prostate is a novel blood test to diagnose and predict clinically significant prostate cancer. This test is currently in development, with patients in Alberta enrolled in clinical trials to validate this simple blood test for future use in Alberta and beyond.

How they are changing the world

John Lewis thanks a “perfect combination” of research, academic conditions, infrastructure, and philanthropic support.

Why Edmonton?

Prostate cancer is the most common cancer among men. Unfortunately, overdiagnosis and overtreatment are critical issues in prostate cancer screening. The ClarityDX Prostate test aims to accurately find and pinpoint the clinically significant disease early on so that patients do not have to undergo unnecessary invasive tests and treatments. This test has the potential to save the health care system money and improve the lives of men diagnosed with prostate cancer, and their families.

What does the future look like?

Answers found unlocking this test may lead to ground-breaking tests for other cancers. John Lewis’ team is currently collaborating with others to come up with tests to better diagnose and predict ovarian and pancreatic cancers.

“This test requires just two drops of blood. It couldn’t be easier.”

Share This